Harnessing inorganic nanomaterials for chemodynamic cancer therapy / Dhelal F Mohammed, Hussein A Madlool, Mohammed Faris, Bashar Hadi Shalan, Huda Hadi Hasan, Nidaa F Azeez, Fatima Hashim Abbas
The most important aspect of chemodynamic therapy (CDT) is the harnessing of Fenton or Fenton-like chemistry for cancer therapy within the tumor microenvironment, which occurs because of the moderate acidity and overexpressed H2O2in the tumor microenvironment. Hydroxyl radicals (•OH) produced within tumor cells via Fenton and Fenton-like reactions cause cancer cell death. Reactive oxygen species-mediated CDT demonstrates a desired anticancer impact without the need for external stimulation or the development of drug resistance. Cancer therapy based on CDT is known as a viable cancer therapy modality. This review discusses the most recent CDT advancements and provides some typical instances. As a result, potential methods for further improving CDT efficiency under the guidance of Fenton chemistry are offered. 2 2 • Plain language summary Cancer is one of the leading causes of death worldwide. Unfortunately, conventional treatments do not greatly increase the quality of life or survival rate of cancer patients. So, coming up with new, less invasive ways to treat cancer would be an important way to increase the number of cancer patients who survive. Chemodynamic therapy, a new cancer treatment modality, uses intracellular hydrogen peroxide as a fantastic ‘Trojan horse’ to produce highly toxic hydroxyl radicals (•OH) to kill cancer cells. This review discusses the most recent advancements in chemodynamic therapy and provides some typical instances. • Tweetable abstract Review of strategies to increase the production of hydroxyl radicals to improve chemodynamic therapy (CDT) performance and discussion of problems and possible outcomes of new and possibly improved CDT techniques.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2023 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mohammed, Dhelal F [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Cancer therapy |
|---|
| Umfang: |
1 Online-Ressource (16 p) |
|---|
| doi: |
10.2217/nnm-2022-0187 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011096063 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011096063 | ||
| 003 | DE-627 | ||
| 005 | 20230713210643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2022-0187 |2 doi | |
| 035 | |a (DE-627)KFL011096063 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2022-0187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Mohammed, Dhelal F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Harnessing inorganic nanomaterials for chemodynamic cancer therapy |c Dhelal F Mohammed, Hussein A Madlool, Mohammed Faris, Bashar Hadi Shalan, Huda Hadi Hasan, Nidaa F Azeez, Fatima Hashim Abbas |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2023 | |
| 300 | |a 1 Online-Ressource (16 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The most important aspect of chemodynamic therapy (CDT) is the harnessing of Fenton or Fenton-like chemistry for cancer therapy within the tumor microenvironment, which occurs because of the moderate acidity and overexpressed H2O2in the tumor microenvironment. Hydroxyl radicals (•OH) produced within tumor cells via Fenton and Fenton-like reactions cause cancer cell death. Reactive oxygen species-mediated CDT demonstrates a desired anticancer impact without the need for external stimulation or the development of drug resistance. Cancer therapy based on CDT is known as a viable cancer therapy modality. This review discusses the most recent CDT advancements and provides some typical instances. As a result, potential methods for further improving CDT efficiency under the guidance of Fenton chemistry are offered. 2 2 • Plain language summary Cancer is one of the leading causes of death worldwide. Unfortunately, conventional treatments do not greatly increase the quality of life or survival rate of cancer patients. So, coming up with new, less invasive ways to treat cancer would be an important way to increase the number of cancer patients who survive. Chemodynamic therapy, a new cancer treatment modality, uses intracellular hydrogen peroxide as a fantastic ‘Trojan horse’ to produce highly toxic hydroxyl radicals (•OH) to kill cancer cells. This review discusses the most recent advancements in chemodynamic therapy and provides some typical instances. • Tweetable abstract Review of strategies to increase the production of hydroxyl radicals to improve chemodynamic therapy (CDT) performance and discussion of problems and possible outcomes of new and possibly improved CDT techniques | ||
| 653 | |a cancer therapy | ||
| 653 | |a chemodynamic therapy | ||
| 653 | |a combination therapy | ||
| 653 | |a Fenton-like reaction | ||
| 653 | |a Fenton reaction | ||
| 653 | |a inorganic nanoparticles | ||
| 653 | |a nanoagent | ||
| 653 | |a nanomaterials | ||
| 653 | |a ROS | ||
| 653 | |a TME | ||
| 700 | 1 | |a Madlool, Hussein A |e verfasserin |4 aut | |
| 700 | 1 | |a Faris, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Shalan, Bashar Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Huda Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Azeez, Nidaa F |e verfasserin |4 aut | |
| 700 | 1 | |a Abbas, Fatima Hashim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2022-0187 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||